8-K: Canopy Growth Q2 FY2026: Strong Canada Sales, Improved EBITDA

Canopy Growth reports improved Q2 FY2026 financial results with significant growth in Canada adult-use and medical cannabis revenue, alongside strengthened balance sheet and reduced Adjusted EBITDA loss.

Summary

• Consolidated net revenue in Q2 FY2026 was $67MM, representing an increase of 6% compared to Q2 FY2025.
• Cannabis net revenue in Q2 FY2026 was $51MM, an increase of 12% compared to Q2 FY2025.
• Canada adult-use cannabis net revenue increased 30% to $24MM in Q2 FY2026, driven by infused pre-roll joints and new All-In-One vapes.
• Canada medical cannabis net revenue increased 17% to $22MM in Q2 FY2026, due to more insured patients, larger order sizes, and a wider product assortment.
• International markets cannabis net revenue decreased 39% to $5MM, primarily due to supply chain challenges in Europe.
• Storz & Bickel net revenue decreased 10% to $16MM, impacted by strong prior year sales and consumer economic uncertainty, partially offset by the new VEAZY product launch.
• Consolidated gross margin was 33% in Q2 FY2026, a decrease of 200 basis points year-over-year but an increase of 800 basis points sequentially.
• Cannabis gross margin was 31% in Q2 FY2026, down from 36% in Q2 FY2025, mainly due to lower international sales and higher inventory provisions.
• Selling, General and Administrative (SG&A) expenses decreased 13% year-over-year, with $21MM of annualized savings captured since March 1, 2025.
• Operating loss from continuing operations improved 63% to $17MM in Q2 FY2026.
• Adjusted EBITDA loss was $3MM in Q2 FY2026, an improvement from $6MM in Q2 FY2025.
• Year-to-date free cash flow outflow was $31MM as of Q2 FY2026, a significant reduction from $112MM in Q2 FY2025.
• Cash and cash equivalents stood at $298MM at September 30, 2025, exceeding debt balances by $70MM, which resolved conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern.
• The Company made prepayments totaling US$50MM against its senior secured term loan in Q2 FY2026.

Sentiment

Score: 7

Explanation: The filing shows significant improvements in key financial metrics, particularly in Canadian market performance, reduced losses, and a strengthened balance sheet, resolving going concern issues. While international sales and Storz & Bickel faced headwinds, the overall trajectory is positive towards profitability and financial stability.

Positives

• Canada adult-use cannabis net revenue increased 30% in Q2 FY2026 and 37% year-to-date.
• Canada medical cannabis net revenue increased 17% in Q2 FY2026 and 15% year-to-date.
• Cash and cash equivalents of $298MM exceed debt balances by $70MM, resolving previous substantial doubt concerning the Company's ability to continue as a going concern.
• Adjusted EBITDA loss improved to $3MM in Q2 FY2026 from $6MM in Q2 FY2025.
• Operating loss from continuing operations improved 63% to $17MM in Q2 FY2026.
• Selling, General and Administrative (SG&A) expenses decreased 13% year-over-year, with $21MM of annualized savings captured since March 1, 2025.
• Year-to-date free cash flow outflow significantly reduced to $31MM from $112MM in Q2 FY2025.
• Storz & Bickel gross margin increased 600 basis points to 38% in Q2 FY2026.
• Consolidated gross margin increased sequentially by 800 basis points compared to Q1 FY2026.

Negatives

• International markets cannabis net revenue decreased 39% to $5MM in Q2 FY2026.
• Storz & Bickel net revenue decreased 10% to $16MM in Q2 FY2026.
• Consolidated gross margin decreased 200 basis points year-over-year to 33% in Q2 FY2026.
• Cannabis gross margin decreased to 31% in Q2 FY2026 from 36% in Q2 FY2025.
• Supply chain challenges in Europe impacted international cannabis revenue.
• Consumer economic uncertainty in key markets impacted Storz & Bickel sales.
• Tariff-related pressures may offset near-term Storz & Bickel performance in certain markets such as the United States.

Risks

• Uncertainty regarding the application of U.S. state and federal law to cannabis and hemp products.
• Ability to refinance debt as and when required on terms favorable and comply with covenants contained in debt facilities and instruments.
• Impacts of the Company's strategy to accelerate entry into the U.S. cannabis market through Canopy USA.
• Risks that the Trust's future ownership interest in Canopy USA is not quantifiable, and the Trust may have significant ownership and influence over Canopy USA.
• Risks in the event that Acreage cannot satisfy its debt obligations as they become due.
• Volatility in and/or degradation of general economic, market, industry or business conditions, including tariffs, inflation, interest rates, and trade policy.
• Risks relating to the evolving regulatory landscape in the United States and current/future operations in emerging markets.
• Compliance with applicable environmental, economic, health and safety, energy and other policies and regulations, particularly health concerns with respect to vaping.
• Inherent uncertainty associated with projections, future product development, and changes in regulatory requirements.
• Reliance on licenses issued by and contractual arrangements with various federal, state, and provincial governmental authorities.
• Third-party manufacturing and transportation risks.
• Exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality.
• Risks relating to inventory write-downs and the ability to manage disruptions in credit markets or changes to credit ratings.
• The potential effects of judicial, regulatory, or other proceedings, litigation, or investigations on the business.
• Risks associated with divestment and restructuring, and the anticipated effects of actions of third parties such as competitors or regulatory authorities.
• Risks related to stock exchange restrictions and the protection and enforcement of intellectual property rights.
• Risks related to exchangeable shares having different rights from common shares and the potential lack of a trading market for exchangeable shares.

Future Outlook

The Company expects robust innovation and tighter alignment with cannabis boards and retailers to drive Canada adult-use cannabis top-line growth in the second half of fiscal year 2026. European medical cannabis operations are anticipated to stabilize and improve by the end of fiscal year 2026. Sequential growth in Storz & Bickel net revenue is expected in the third quarter ended December 31, 2025, supported by VEAZY sales and the holiday season, though tariff pressures may impact U.S. performance. The Company is also focused on lowering its cost of goods sold through process streamlining, smart investments for yield and quality, and tighter supplier management.

Management Comments

• "We're building a stronger, more competitive company defined by continued momentum in Canada adult-use cannabis, consistent growth in Canada medical cannabis, and a disciplined approach to strengthening our balance sheet. Together, these actions give me confidence in our ability to sustain progress and deliver results for quarters to come." Luc Mongeau, Chief Executive Officer
• "Our financial discipline continues to improve our path to profitability. Through cost reductions, margin expansion, and balance sheet strength, we're building a more resilient company poised for long term success." Tom Stewart, Chief Financial Officer

Industry Context

The cannabis industry in Canada continues to mature, with companies like Canopy Growth focusing on market share in adult-use and medical segments. The challenges in international markets, particularly Europe, reflect broader regulatory and supply chain complexities faced by many global cannabis players. The mention of consumer economic uncertainty impacting Storz & Bickel sales suggests a broader trend affecting discretionary spending on premium products. The company's focus on cost reductions and balance sheet strength aligns with a general industry trend towards profitability and sustainability over aggressive expansion.

Comparison to Industry Standards

• Canopy Growth's 30% growth in Canada adult-use cannabis revenue is strong, potentially outperforming some competitors in a maturing market, indicating effective commercial strategy and execution.
• The 17% growth in Canada medical cannabis revenue is notable, suggesting successful patient acquisition and retention strategies, possibly leveraging its Spectrum Therapeutics brand against other medical providers.
• The 39% decline in international cannabis revenue due to supply chain issues highlights a common vulnerability for companies with global operations, contrasting with more stable domestic markets.
• The improvement in Adjusted EBITDA loss from $6MM to $3MM, alongside significant free cash flow reduction, indicates progress towards profitability and operational efficiency, a key focus for many cannabis companies struggling with past over-expansion.
• The resolution of the "going concern" doubt is a significant positive, differentiating Canopy Growth from some peers who continue to face liquidity challenges.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, reduced losses, strengthened balance sheet, and resolution of going concern doubt. Potential for future growth in Canadian markets.
• Employees: Focus on cost reductions and efficiency improvements could imply ongoing scrutiny of operational expenses, potentially impacting staffing or resource allocation.
• Customers: Increased product assortment and innovation in Canada adult-use and medical markets. Potential for improved supply chain in Europe.
• Creditors: Positive impact from prepayments on senior secured term loan and improved cash position, reducing credit risk.

Next Steps

• Drive Canada adult-use cannabis top-line growth in the second half of FY2026 through innovation and retailer alignment.
• Improve supply chain execution in the European medical cannabis business, with stabilization and improvement expected by the end of FY2026.
• Support sequential growth in Storz & Bickel net revenue in Q3 FY2026 through VEAZY sales ramp-up and the holiday season.
• Meaningfully lower cost of goods sold through streamlining processes, smart investments, and tighter supplier management.
• Monitor the outcome of the vote relating to the Government of Canada's proposed 2025 federal budget, including adjustment to the medical cannabis benefit program.

Key Dates

Recommendation

The company has shown significant progress in improving its financial health, particularly in Canada and in reducing its Adjusted EBITDA loss and free cash flow burn. The resolution of the going concern doubt is a major positive. However, challenges remain in international markets and with Storz & Bickel revenue, and the path to sustained profitability is still ongoing. While the improvements are notable, the stock may still be considered speculative given the inherent risks in the cannabis industry and the need for continued execution. A "hold" recommendation reflects the positive momentum while acknowledging the remaining hurdles and the need for further evidence of consistent, profitable growth.

Keywords

cannabis, adult-use, medical cannabis, Storz & Bickel, vaporizers, financial results, EBITDA, revenue, Canada, Canopy Growth, CGC, WEED, Q2 FY2026